INTRODUCTION {#s1}
============

Locally advanced rectal cancer (LARC) is associated with poor prognosis and a high risk of developing local and distant metastases \[[@R1]\]. Its management requires the application of a multimodal therapy, which includes neoadjuvant treatments, surgery, and eventually, adjuvant treatments. The cornerstone of the current therapeutic strategies for LARC is to tailor the different available treatments to the patient and tumor characteristics in order to achieve the best tumor response with the minimal associated morbidity \[[@R2]\].

After LARC diagnosis, neoadjuvant chemoradiation therapy (NCRT) is used to decrease the risk of local recurrence and obtain downstaging of the primary tumor before surgery \[[@R3]\]. Complete tumor regression, established as a pathological complete response (pCR; ypT0N0V0), is observed in 10% to 30% of patients \[[@R4]--[@R6]\], whereas up to 20% of patients are non-responders \[[@R7]\].

Magnetic resonance imaging (MRI) is nowadays considered the most accurate test to define locoregional clinical staging of rectal cancer \[[@R8]\]. Indications for NCRT in case of LARC should be based on the MRI study performed to stage the primary tumor and assess its resectability (i.e., pretreatment MRI). Moreover, the radiologic measuring of the pelvis, namely, pelvimetry, has been proposed as a helpful tool in determining important predictors of surgical difficulties that may need to be taken into account when planning cancer resection \[[@R9]--[@R11]\].

Following NCRT, surgical excision remains the best option to improve disease-free and overall survival in patients with LARC \[[@R2], [@R12], [@R13]\]. The oncologic objective is to achieve complete mesorectal excision with clear resection margins \[[@R14]\]. Although it is still under debate \[[@R14]--[@R16]\], the use of laparoscopy for rectal cancer has progressively increased with laparoscopic total mesorectal excision (L-TME) and laparoscopic abdominal perineal resection (L-APR) as the most frequently performed procedures in high-volume referral hospitals. Although it improves patients' prognosis \[[@R17]\], surgery may be also associated with significant morbidity and sequelae, such as fecal incontinence or bladder and sexual dysfunction \[[@R18], [@R19]\]. Therefore, it has been recently suggested that in selected patients with a clinical complete response to NCRT, a "watch and wait" approach, which avoids surgery in favor of observation, might be justified \[[@R20]\]. Also in this setting, the accuracy of the method for the assessment of tumor response to treatment is of cardinal importance and must differentiate radiation-induced fibrosis or edema from residual cancer in a reliable way. Restaging MRI, performed after the completion of NCRT, has been shown to be acceptably accurate and reproducible in assessing tumor response in some studies but is not routinely performed nor unanimously accepted \[[@R21]--[@R27]\].

The *EuMaRCS* (European MRI and Rectal Cancer Surgery) study group aimed to investigate the role of pretreatment and restaging MRI in rectal cancer therapy by analyzing radiological parameters (including pelvimetry) in relation to clinical and histopathological outcomes in order to 1) assess the predictors of surgical difficulties and survival related to the tumor and the patient\'s characteristics and 2) estimate the diagnostic accuracy of restaging MRI.

RESULTS {#s2}
=======

Initially, 184 patients were selected based upon the described inclusion criteria. However, due to the lack of essential MRI sequences or incomplete protocols, which prevented re-evaluation and measurements, 14 patients were excluded. Finally, 170 patients composed the study population.

Demographic, operative and histopathological variables {#s2_1}
------------------------------------------------------

Demographic, operative, and histopathological variables are displayed in Table [1](#T1){ref-type="table"}. No difference was noted between males and females, except that male patients were more frequently transfused than females (*p* = 0.033). Tumor sterilization (ypT0N0V0) was noted in 25 (22.9%) male and 14 (23%) female patients (*p* = 1). Two male patients (1.17%) presented with ypT0N+. All patients had \>2 lymph nodes harvested. A successful resection was obtained in 85 (78%) male and 48 (78.7%) female patients (*p* = 1).

###### Demographic, operative and histopathologic variables of patients undergone laparoscopic surgical resection of LARC after NCRT

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                      Whole sample\    Male patients\     Female patients\   *P* Values
                                                                                 *n* = 170        *n* = 109          *n* = 61           
  ------------------------------------------------------------------------------ ---------------- ------------------ ------------------ ------------
  ***Demographic and Clinical Variables***                                                                                              

  **Age** (yr) \[median (range)\]                                                61 (27--86)      62 (27--86)        59.1 (28.5--86)    0.405

  **Male gender** \[*n* (%)\]                                                    109 (64.1)       \-                 \-                 NA

  **BMI** (kg/m^2^) \[median (range)\]                                           26 (17--46.4)    26 (18.25--38.5)   25.8 (17--46.4)    0.703

  **Obesity** (BMI ≥ 30 kg/m^2^) \[*n* (%)\]                                     32 (18.8)        19 (17.4)          13 (21.3)          0.539

  **ASA score** I/II/III \[*n*\]                                                 29/86/55         19/50/40           10/36/15           0.209

  **Albumin serum level** (g/L) \[mean (SD)\]                                    39.29 (5.46)     39.19 (6.18)       39.49 (3.65)       0.695

  **Preoperative serum CEA** (U/mL) \[mean (SD)\]                                9.38 (32.07)     11.66 (39.25)      5.07 (6.36)        0.303

  **Charlson score** \[median (range)\]                                          3 (2--11)        3 (2--11)          3 (2--8)           0.280

  **CR possum score** \[median (range)\]                                         9 (6--17)        9 (6--15)          9 (6--17)          0.760

  **Comorbidity** \[*n* (%)\]                                                    108 (63.5)       72 (66.1)          36 (59)            0.317

  **Comorbidity** \>1 \[*n* (%)\]                                                62 (36.5)        45 (41.3)          17 (27.9)          0.211

  **Diabetes** \[*n* (%)\]                                                       34 (20)          24 (22)            10 (16.4)          0.266

  **Cardiovascular diseases** \[*n* (%)\]                                        55 (32.4)        39 (35.8)          16 (26.2)          0.634

  **Pulmonary diseases** \[*n* (%)\]                                             26 (15.3)        21 (19.3)          5 (8.2)            0.154

  **Kidney failure** \[*n* (%)\]                                                 8 (4.7)          4 (3.7)            4 (6.6)            0.692

  **Neurocognitive disorders** \[*n* (%)\]                                       5 (2.9)          3 (2.8)            2 (3.3)            0.977

  **Previous abdominal surgery** \[*n* (%)\]                                     50 (29.4)        27 (24.8)          23 (37.7)          0.206

  **Surgical laparoscopic procedures** \[*n* (%)\]                                                                                      

   - TME with primary anastomosis                                                136 (80)         85 (78)            51 (83.6)          0.674

   - Low Hartmann procedure with TME                                             13 (7.6)         9 (8.3)            4 (6.6)            

   - APR                                                                         21 (12.4)        15 (13.8)          6 (9.8)            

  ***Operative* and *Postoperative Variables***                                                                                         

  **Operative time (min)** \[median (range)\]                                    240 (120--550)   235 (130--550)     241.5 (120--550)   0.818

  **Conversion to laparotomy** \[*n* (%)\]                                       11 (6.5)         10 (9.2)           1 (1.6)            0.100

  **Operative blood loss (mL)** \[median (range)\]                               60 (0--2000)     60 (0--2000)       50 (0--1500)       0.775

  **Number of transfused patients** \[*n* (%)\]                                  13 (7.6)         12 (11)            1 (1.6)            **0.033**

  **Time to flatus** \[mean (SD)\]                                               2.88 (3.57)      3.01 (4.23)        2.64 (1.81)        0.188

  **Return to regular diet** \[mean (SD)\]                                       5.45 (5.47)      5.96 (6.38)        4.52 (3.10)        0.915

  ***ISGRC* anastomotic leakage§ \[*n* (%)\]**                                                                                          0.205

   - A                                                                           3 (2.2)          2 (2.4)            1 (2)              

   - B                                                                           11 (8.1)         9 (10.6)           2 (3.9)            

   - C                                                                           8 (5.9)          7 (8.2)            1 (2)              

  **Dindo- Clavien classification of postoperative complications** \[*n* (%)\]                                                          

   - I/II                                                                        48 (68.6)        34 (64.2)          14 (82.4)          0.353

   - III/IV                                                                      21 (30)          18 (34)            3 (17.6)           

   - V                                                                           1 (1.4)          1 (1.9)            0                  

  **Reoperation** \[*n* (%)\]                                                    16 (9.4)         13 (11.9)          3 (4.9)            0.303

  **Hospital stay, days** \[median (range)\]                                     10 (4--70)       10 (4--70)         10 (5--30)         0.968

  **Mortality at 90 days** \[*n* (%)\]                                           0                0                  0                  \-

  **Readmission within 60 days** \[*n* (%)\]                                     18 (10.6)        14 (12.8)          4 (6.6)            0.437

  **Adjuvant chemotherapy** \[*n* (%)\]                                          117 (68.8)       74 (67.9)          43 (70.5)          0.837

  ***Histopathological (yp) Variables***                                                                                                

  **Tumor largest dimension (cm)** \[mean (SD)\]                                 2.38 (1.77)      2.32 (1.54)        2.48 (2.11)        0.719

  **Tumor regression grade (MANDARD)**\                                                                                                 0.668
  \[*n* (%)\]                                                                                                                           

   - I                                                                           39 (22.9)        25 (22.9)          14 (23)            

   - II                                                                          34 (20)          25 (22.9)          9 (14.8)           

   - III                                                                         53 (31.2)        34 (31.2)          19 (31.1)          

   - IV                                                                          42 (24.7)        24 (22)            18 (29.5)          

   - V                                                                           2 (1.2)          1 (0.9)            1 (1.6)            

  **ypT stage** \[*n* (%)\]                                                                                                             0.991

   - ypT0                                                                        40 (23.5)        26 (23.9)          14 (23)            

   - ypT1                                                                        10 (5.9)         6 (5.5)            4 (6.6)            

   - ypT2                                                                        49 (28.8)        31 (28.4)          18 (29.5)          

   - ypT3                                                                        61 (35.9)        40 (36.7)          21 (34.4)          

   - ypT4a                                                                       6 (3.5)          4 (3.7)            2 (3.3)            

   - ypT4b                                                                       4 (2.4)          2 (1.8)            2 (3.3)            

  **ypN stage** \[*n* (%)\]                                                                                                             0.105

   - yN0                                                                         121 (71.2)       78 (71.6)          43 (70.5)          

   - yN1                                                                         21 (12.4)        14 (12.8)          7 (11.5)           

   - yN1a                                                                        10 (5.9)         3 (2.8)            7 (11.5)           

   - yN1b                                                                        6 (3.5)          4 (3.7)            2 (3.3)            

   - yN1c                                                                        1 (0.6)          0                  1 (1.6)            

   - yN2                                                                         8 (4.7)          7 (6.4)            1 (1.6)            

   - yN2a                                                                        3 (1.8)          3 (2.8)            0                  

  **ypCRM mm** \[mean (SD)\]                                                     10.01 (8.27)     9.76 (8.04)        10.42 (8.75)       0.797

  **Positive ypCRM** \[*n* (%)\]                                                 16 (9.4)         11 (10.1)          5 (8.2)            0.789

  **ypDRM mm** \[mean (SD)\]                                                     31.58 (24.15)    31.35 (21.69)      31.99 (28.36)      0.757

  **Positive ypDRM** \[*n* (%)\]                                                 6 (3.5)          3 (2.8)            3 (4.9)            0.668

  **Complete mesorectal excision** \[*n* (%)\]                                   144 (84.7)       92 (84.4)          52 (85.2)          

   - ypCRM ≤ 1 mm, ypDRM+                                                        2 (1.4)          1 (1.1)            1 (1.9)            0.864

   - ypCRM ≤ 1 mm, ypDRM−                                                        8 (5.6)          5 (5.4)            3 (5.8)            

   - ypCRM \> 1 mm, ypDRM+                                                       1 (0.7)          1 (1.1)            0                  

   - ypCRM \> 1 mm, ypDRM--                                                      133 (92.4)       85 (92.4)          48 (92.3)          

  **Nearly complete mesorectal excision** \[*n* (%)\]                            20 (11.8)        14 (12.8)          6 (9.8)            

   - ypCRM ≤ 1 mm, ypDRM+                                                        2 (10)           1 (7.1)            1 (16.7)           0.418

   - ypCRM ≤ 1 mm, ypDRM--                                                       3 (15)           3 (21.4)           0                  

   - ypCRM \> 1 mm, ypDRM+                                                       0                0                  0                  

   - CRM \> 1 mm, DRM−                                                           15 (75)          10 (71.4)          5 (83.3)           

  **Incomplete mesorectal excision** \[*n* (%)\]                                 6 (3.5)          3 (2.8)            3 (4.9)            

  \- ypCRM ≤ 1 mm, ypDRM+                                                        0                0                  0                  

  \- ypCRM ≤ 1 mm, ypDRM−                                                        1 (16.7)         1 (33.3)           0                  0.368

  \- ypCRM \> 1 mm, ypDRM+                                                       1 (16.7)         0                  1 (33.3)           

  \- ypCRM \> 1 mm, ypDRM−                                                       4 (67.7)         2 (66.7)           2 (66.7)           

  **Harvested lymph nodes** \[mean (SD)\]                                        13.55 (5.93)     13.51 (6.01)       13.62 (5.84)       0.618

  **Lymphovascular invasion** \[*n* (%)\]                                        19 (11.2)        14 (12.8)          5 (8.2)            0.451

  **Perineural invasion** \[*n* (%)\]                                            20 (11.8)        11 (10.1)          9 (14.8)           0.457

  **Tumor deposit** \[*n* (%)\]                                                  62 (36.5)        44 (40.4)          18 (29.5)          0.370

  **Tumor grade** \[*n* (%)\]^\*^                                                                                                       0.690

   - Well differentiated                                                         55 (41.9)        34 (40.5)          21 (44.7)          

   - Moderately differentiated                                                   49 (37.4)        30 (35.7)          19 (40.4)          

   - Poorly differentiated                                                       27 (20.6)        20 (23.8)          7 (14.9)           
  --------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented for the whole study sample and by gender.

^§^Calculated from laparoscopic TME with primary anastomosis (*n* = 136).

^\*^Calculated from non-sterilized tumors (*n* = 131).

BMI stands for body mass index; ASA, for American Society of Anesthesiology; CEA, for carcinoembryonic antigen; TME, for total mesorectal excision; APR, for abdominoperineal resection; T, for tumor stage; N, for node stage; CRM, for circumferential resection margin; and DRM, for distal resection margin.

Pelvimetry {#s2_2}
----------

Measurements on the pretreatment MRI are shown in Table [2](#T2){ref-type="table"}. Males and females differed significantly for the majority of the recorded measures of pelvimetry, showing that male patients generally have a narrower and deeper pelvis than female patients.

###### Pelvimetry of patients with LARC

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                                         Whole sample\    Male patients\   Female patients\   *P* Values
                                                                                                    *n* = 170        *n* = 109        *n* = 61           
  ------------------------------------------------------------------------------------------------- ---------------- ---------------- ------------------ --------------
  ***Pelvimetry***                                                                                                                                       

  *Transverse measures*                                                                                                                                  

  **Interischiatic spinous distance (mid-pelvic plane)**\                                           97.65 (11.22)    92 (8.26)        107.66 (8.45)      **\<0.0001**
  (mm) \[mean (SD)\]                                                                                                                                     

  **Intertuberous distance (outlet pelvic plane)**\                                                 120.11 (16.36)   113.46 (14.65)   131.89 (12.07)     **\<0.0001**
  (mm) \[mean (SD)\]                                                                                                                                     

  **Interacetabular distance (inlet pelvic plane)** (mm) \[mean (SD)\]                              124.68 (8.04)    122.93 (7.64)    127.79 (7.86)      **\<0.0001**

  *Sagittal measures*                                                                                                                                    

  **Pelvic outlet length (pubic symphysis to the tip of the coccyx distance)** (mm) \[mean (SD)\]   86.87 (10.91)    85.79 (11.28)    88.78 (10.02)      0.082

  **Mid-inlet length (pelvic depth)** (mm) \[mean (SD)\]                                            105.61 (11.24)   108.61 (11.34)   100.22 (8.84)      **\<0.0001**

  **Pelvic inlet length (promontory to pubic symphysis distance)** (mm) \[mean (SD)\]               109.43 (12.03)   106.82 (10.26)   114.05 (13.55)     **\<0.0001**

  **Promontory to coccyx distance** (mm) \[mean (SD)\]                                              120.37 (15.12)   123.44 (16.04)   114.85 (11.51)     **\<0.0001**

  **Length of the anterior sacrococcygeal curve** (mm) \[mean (SD)\]                                155.11 (20.19)   157.24 (23)      151.27 (13.09)     **\<0.0001**

  **S3 (middle third) to promontory distance** (mm) \[mean (SD)\]                                   80.02 (7.2)      81.05 (7.65)     78.16 (5.93)       **0.003**

  **S3 (middle third) to coccyx distance** (mm) \[mean (SD)\]                                       64.64 (9.53)     67.05 (9.5)      60.39 (8.03)       **\<0.0001**

  **Pubic tubercle height** (mm) \[mean (SD)\]                                                      52.06 (10.03)    53.60 (11.96)    49.33 (3.79)       **\<0.0001**

  *Angles*                                                                                                                                               

  **Angle 1 (°)** \[mean (SD)\]                                                                     92.72 (10.11)    92.88 (9.44)     92.44 (11.29)      0.706

  **Angle 2 (°)** \[mean (SD)\]                                                                     111.45 (16.82)   111.82 (14.86)   110.79 (19.98)     0.544

  **Angle 3 (°)** \[mean (SD)\]                                                                     113.43 (12.35)   111.16 (12.05)   117.47 (11.93)     **0.002**

  **Angle 4 (°)** \[mean (SD)\]                                                                     126.19 (7.18)    126.71 (7.29)    125.27 (6.94)      0.225

  **Angle 5 (°)** \[mean (SD)\]                                                                     94.71 (6.41)     96.12 (5.77)     92.18 (6.96)       **\<0.0001**

  **Promontory to the top of the pubic symphysis angle** (°) \[mean (SD)\]                          63.46 (6.77)     63.23 (6.28)     63.87 (7.62)       0.624

  **Promontory to the lowest tip of the pubic symphysis angle** (°) \[mean (SD)\]                   39.82 (5.37)     38.92 (4.98)     41.44 (5.71)       **0.003**

  *Surface measures*                                                                                                                                     

  S**urface of the sacrum-coccyx concavity** (cm^2^) \[mean (SD)\]                                  34.02 (10.37)    35.63 (11.71)    31.11 (6.53)       0.001

  **Lesser pelvis surface** (cm^2^) \[mean (SD)\]                                                   105.76 (13.03)   106.85 (12.55)   103.79 (13.74)     0.179

  **Rectal surface at the level of the low-mid-rectum junction** (cm^2^) \[mean (SD)\]              8.08 (3.61)      8.66 (3.83)      6.94 (2.82)        **0.008**

  **Mesorectal surface at the level of the low-mid-rectum junction** (cm^2^) \[mean (SD)\]          3.95 (1.97)      3.99 (2.04)      3.86 (1.84)        0.644

  **Presacral fascia surface at the level of the low-mid-rectum junction** (cm^2^) \[mean (SD)\]    12.06 (4.66)     12.7 (4.99)      10.8 (3.65)        **0.029**

  **Rectal surface at the level of the mid-high rectum junction** (cm^2^) \[mean (SD)\]             7.45 (4.25)      7.52 (4.36)      7.31 (4.08)        0.854

  **Mesorectum surface at the level of the mid-high rectum junction** (cm^2^) \[mean (SD)\]         19.69 (6.89)     19.63 (5.6)      19.82 (8.93)       0.778

  **Presacral fascia surface at the level of the mid-high rectum junction** (cm^2^) \[mean (SD)\]   27.21 (8.55)     27.25 (7.56)     27.13 (10.28)      0.956

  *Derivate measures*                                                                                                                                    

  **Ratio of the pelvic inlet to the pelvic depth** \[mean (SD)\]                                   1.04 (0.16)      0.99 (0.13)      1.14 (0.17)        **\<0.0001**

  **Ratio of the pelvic outlet to angle 2** \[mean (SD)\]                                           0.85 (0.7)       0.81 (0.51)      0.91 (0.94)        **0.026**

  **Ratio of the pelvic outlet to angle 3** \[mean (SD)\]                                           0.77 (0.15)      0.78 (0.16)      0.76 (0.14)        0.692

  **Ratio of angle 2 to angle 3** \[mean (SD)\]                                                     1.12 (0.95)      1.07 (0.79)      1.22 (1.19)        **0.048**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Measures were taken on the pretreatment MRI. Data are presented for the whole study sample and by gender.

Pretreatment and restaging MRI {#s2_3}
------------------------------

The tumor characteristics evaluated on the pretreatment and restaging MRIs are shown in Table [3](#T3){ref-type="table"}. No significant differences were noted between males and females. Based on the primary tumor staging on the pretreatment MRI, 84 patients (49.4%) were staged as \>cT3b and 146 (85.8%) as cN+. Based on the restaging MRI, 41 patients (24.1%) were staged as \>yT3b; 56 (32.9%), as yN+. A significant decrease in the tumors' largest dimension (*p \<* 0.0001) and volume (*p* \< 0.0001) was observed between pretreatment and restaging MRI assessment, without differences between genders (*p* = 0.262 and *p* = 0.661, respectively).

###### Pretreatment MRI and restaging MRI characteristics of patients with LARC undergone laparoscopic resection after NCRT

  --------------------------------------------------------------------------------------------------------------------
  Variables                                           Whole sample\   Male patients\   Female patients\   *P* Values
                                                      *n* = 170       *n* = 109        *n* = 61           
  --------------------------------------------------- --------------- ---------------- ------------------ ------------
  ***Pretreatment MRI measurements***                                                                     

  **Tumor largest dimension** (mm) \[mean (SD)\]      49.57 (17.44)   49.80 (18.11)    49.17 (16.32)      0.891

  **Tumor circumferential extension** \[*n* (%)\]                                                         0.119

   **- 25%**                                          9 (5.3)         7 (6.4)          2 (3.3)            

   **- 50%**                                          52 (30.6)       30 (27.5)        22 (36.1)          

   **- 75%**                                          53 (31.2)       30 (27.5)        23 (37.7)          

   **- 100%**                                         56 (32.9)       40 (38.5)        14 (23)            

  **Tumor height** (mm) \[mean (SD)\]                 49.14 (17.99)   49.42 (18.7)     48.64 (16.8)       0.811

  **DRM** (mm) \[mean (SD)\]                          39.49 (28.41)   38.86 (27.58)    40.59 (30.02)      0.739

  **cT stage** \[*n* (%)\]                                                                                0.672

   - cT1                                              0               0                0                  

   - cT2                                              15 (8.8)        8 (7.3)          7 (11.5)           

   - cT3a                                             17 (10)         12 (11)          5 (8.2)            

   - cT3b                                             54 (31.8)       33 (30.3)        21 (34.4)          

   - cT3c                                             33 (39.4)       25 (22.9)        8 (13.1)           

   - cT3d                                             15 (8.8)        8 (7.3)          7 (11.5)           

   - cT4a                                             23 (13.5)       15 (13.8)        8 (13.1)           

   - cT4b                                             13 (7.6)        8 (7.3)          5 (8.2)            

  **cN stage** \[*n* (%)\]                                                                                0.699

   - cN0                                              24 (14.1)       17 (15.6)        7 (11.5)           

   - cN1                                              97 (57.1)       60 (55)          37 (60.7)          

   - cN2                                              49 (28.8)       32 (29.4)        17 (27.9)          

  **CRM** (mm) \[mean (SD)\]                          10.89 (9.33)    11.52 (9.98)     9.71 (7.96)        0.377

  **Maximum tumor thickness** (mm)\[mean (SD)\]       15.72 (9.05)    15.47 (8.93)     16.16 (9.31)       0.873

  **EMVI positive** \[*n* (%)\]                       64 (37.6)       47 (43.1)        17 (27.91)         0.144

  **Tumor volume** (cm^2^) \[mean (SD)\]              29.28 (37.93)   28.46 (36.13)    30.81 (41.4)       0.617

  ***Restaging MRI measurements (ymr)***                                                                  

  **ymrTumor largest dimension** (mm) \[mean (SD)\]   29.88 (15.83)   30.72 (15.54)    28.4 (16.35)       0.543

  **ymrTumor circumferential extension (n%)**                                                             0.417

   **- 0%**                                           31 (18.2)       16 (14.7)        15 (24.6)          

   **- 25%**                                          13 (7.6)        8 (7.3)          5 (8.2)            

   **- 50%**                                          68 (40)         44 (40.4)        24 (39.3)          

   **- 75%**                                          29 (17.1)       19 (17.4)        10 (16.4)          

   **- 100%**                                         29 (17.1)       22 (20.2)        7 (11.5)           

  ymrTumor height                                     28.48 (15.99)   28.81 (15.18)    27.91 (17.45)      0.855

  **ymrDRM** (mm) \[mean (SD)\]                       41.94 (28.5)    41.92 (28.34)    41.93 (29.07)      0.903

  **ymrT stage** \[*n* (%)\]                                                                              0.300

   - ymrT0                                            31 (18.2)       18 (16.5)        13 (21.3)          

   - ymrT1                                            2 (1.2)         2 (1.8)          0                  

   - ymrT2                                            59 (34.7)       38 (34.9)        21 (34.4)          

   - ymrT3                                            1 (0.6)         1 (0.9)          0                  

   - ymrT3a                                           7 (4.1)         6 (5.5)          1 (1.6)            

   - ymrT3b                                           29 (17.1)       17 (15.6)        12 (19.7)          

   - ymrT3c                                           19 (11.2)       10 (9.2)         9 (14.8)           

   - ymrT3d                                           7 (4.1)         6 (5.5)          1 (1.6)            

   - ymrT4a                                           10 (5.9)        9 (8.3)          1 (1.6)            

   - ymrT4b                                           5 (2.9)         2 (1.8)          3 (4.9)            

  **ymrN stage** \[*n* (%)\]                                                                              0.295

   - ymrN0                                            114 (67.1)      71 (65.1)        43 (70.5)          

   - ymrN1                                            52 (30.6)       34 (31.2)        18 (29.5)          

   - ymrN2                                            4 (2.4)         4 (3.7)          0                  

  **ymrCMR status \>2 mm** \[*n* (%)\]                101 (78.9)      67 (79.8)        34 (77.3)          0.821

  ymrTRG score                                                                                            0.198

   - 1                                                44 (25.9)       27 (24.8)        17 (27.9)          

   - 2                                                45 (26.5)       35 (32.1)        10 (16.4)          

   - 3                                                43 (25.3)       27 (24.8)        16 (26.2)          

   - 4                                                36 (21.2)       19 (17.4)        17 (27.9)          

   - 5                                                2 (1.2)         1 (0.9)          1 (1.6)            

  **ymrMaximum tumor thickness** (mm) \[mean (SD)\]   9.27 (6.50)     9.67 (6.44)      8.58 (6.62)        0.216

  **ymrEMVI positive** \[*n* (%)\]                    45 (26.5)       34 (31.2)        11 (18)            0.071

  **ymrTumor volume** (cm^2^) \[mean (SD)\]           10.65 (20.55)   10.49 (19.58)    10.94 (22.47)      0.542
  --------------------------------------------------------------------------------------------------------------------

Data are presented for the whole study sample and by gender.

DRM stands for distal resection margin; CRM, for circumferential resection margin; EMVI, for extramural vascular invasion; and TRG, for tumor regression grade; (ymr) identifies the restaging MRI assessments.

Multivariate analysis outcomes {#s2_4}
------------------------------

Univariate and then multivariate analyses were run to identify factors associated with indicators of surgical difficulties and surgical outcomes (Table [4](#T4){ref-type="table"}). Gender was not associated with any of these indicators. Conversely, the tumor volume and the tumor height assessed on the restaging MRI were associated, respectively, with the operative time and the estimated blood loss. Conversion was predicted by tumor volume, interischial distance, and pubic tubercle height. A ymrCRM \<2 mm was found to be a associated with postoperative complications and successful resection.

###### Multivariate analysis of the association between pelvimetry and MRI characteristics with indicators of operative difficulties and postoperative outcomes on the whole study population (*n* = 170)

  Outcomes                          Predictive Factor                       β Coefficient   *t*          *P* Value
  --------------------------------- --------------------------------------- --------------- ------------ ---------------
  **Operative time**                **ymrTumor volume** *(restaging MRI)*   0.247           2.40         **0.018**
  **Estimated blood loss**          **ymrTumor height** *(restaging MRI)*   0.307           3.01         **0.003**
  **Outcomes**                      **Predictive Factor**                   **OR**          **95% CI**   ***P* Value**
  **Conversion**                    **Interischiatic spinous distance**     0.85            0.74--0.97   **0.018**
                                    **Pubic tubercle height**               1.28            1.01--1.61   **0.042**
                                    **ymrTumor volume** *(restaging MRI)*   1.02            1.01--1.04   **0.005**
  **Postoperative complications**   **Intertuberous distance**              0.97            0.93--0.99   **0.014**
                                    **Angle 1**                             0.94            0.89--0.98   **0.009**
                                    **ymrCRM \< 2 mm** *(restaging MRI)*    3.57            1.38--0.09   **0.008**
  **Successful resection**          **ymrCRM \< 2 mm** *(restaging MRI)*    0.22            0.08--0.59   **0.003**

Only significant predictors are shown.

CRM stands for circumferential resection margin; OR, for odds ratio; and CI, for confidence interval.

Survival outcomes {#s2_5}
-----------------

The mean overall follow-up time was 25.01 months (SD: 18.53 months). The overall survival (OS) and disease-free survival (DFS) curves are shown in Figure [1](#F1){ref-type="fig"}. The 1-, 2- and 3-year OS rates were, respectively, 98%, 91.5% and 89.1% for the male group and 96.3%, 90.5% and 87% for the female group (*p* = 0.164). The mean OS for the male group was 66.12 months (SD: 4.14 months) and that for the female group was 77.53 months (SD: 9.83). The 1-, 2- and 3-year DFS rates were, respectively, 79%, 73.1% and 68.9% for the male group and 87%, 75.2% and 69.4% for the female group (*p* = 0.439). Disease recurrence over the entire follow-up period was observed in 34 patients (20.1%); 23 (21.1%) were males, and 11 (18%) were females (*p* = 0.693). Overall, 6 patients (17.6%) had local recurrence, and 28 patients (82.4%) had distant metastases (including 6 patients who experienced both local and distant recurrence). Distant recurrence included isolated liver metastases (*n* = 7), isolated pulmonary metastases (*n* = 11), liver and pulmonary metastases (*n* = 5), carcinosis (*n* = 3), and systemic metastatic disease (*n* = 2). No gender difference was found (*p* = 0.110). Predictors of OS and DFS are shown in Table [5](#T5){ref-type="table"}. The only significant predictor of OS was the quality of the surgical resection, whereas the stage ymr\>T3b, the achievement of a successful resection, the ypN+ status, and the ypT4 stage were significant predictors of DFS.

![Survival analysis of patients with LARC undergone laparoscopic resection after NCRT\
(**A**) Overall survival by gender; (**B**) Disease-free survival by gender.](oncotarget-09-25315-g001){#F1}

###### Univariate and multivariate Cox regression hazard analyses for predictors of overall and disease-free survival in the whole study sample

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                       Whole study sample (*N* = 169^\*^)                                                                                                     
  ---------------------------------------------------- ------------------------------------ ----------- ------------------ ----------- ------------------- -------------- ------------------- -----------
  **Gender: male vs. female**                          0.52\                                0.171                                      0.75\               0.443                              
                                                       (0.20--1.32)                                                                    (0.37--1.55)                                           

  **Comorbidity ≥1**                                   1.17\                                0.710                                      1\                  0.990                              
                                                       (0.51--2.71)                                                                    (0.49--2.03)                                           

  **L-APR vs. L-TME**                                  0.98\                                0.983                                      0.67\               0.375                              
                                                       (0.29--3.32)                                                                    (0.27--1.62)                                           

  **Tumor height \<4 cm** *(pretreatment MRI)*         0.96\                                0.943                                      1.21\               0.617                              
                                                       (0.39--2.37)                                                                    (0.57--2.6)                                            

  **CRM \<2 mm**                                       1.24\                                0.649                                      **4.14**\           **\<0.0001**                       
                                                       (0.48--3.23)                                                                    **(2.08--8.23)**                                       

  **ymrCRM \<2 mm**                                    1.09\                                0.854                                      **4.14**\           **\<0.0001**                       
                                                       (0.40--2.97)                                                                    **(2.10--8.14)**                                       

  **Tumor largest dimension**                          1.01\                                0.133                                      **1.02**\           **0.006**                          
                                                       (0.99--1.04)                                                                    **(1.1--1.04)**                                        

  **ymrTumor largest dimension**                       1.02\                                0.076                                      **1.03**\           **\<0.0001**                       
                                                       (0.99--1.04)                                                                    **(1.01--1.04)**                                       

  **ymrN+ vs. ymrN0**                                  1.20\                                0.662                                      **2.82**\           **0.001**                          
                                                       (0.53--2.73)                                                                    **(1.53--5.22)**                                       

  **ymr\>T3b stage**                                   **2.64**\                            **0.022**                                  **7.31**\           **\<0.0001**   **2.50**\           **0.029**
                                                       **(1.15--6.08)**                                                                **(3.60--14.80)**                  **(1.09--5.70)**    

  **Intraoperative transfusion**                       1.81\                                0.285                                      1.54\               0.554                              
                                                       (0.61--5.43)                                                                    (0.37--6.42)                                           

  **Conversion to open surgery**                       1.27\                                0.749                                      **3.72**\           **0.004**                          
                                                       (0.29--5.41)                                                                    **(1.53--9)**                                          

  **Postoperative complication**                       1.53\                                0.306                                      1.13\               0.729                              
                                                       (0.67--3.49)                                                                    (0.56--2.25)                                           

  **Unsuccessful vs. successful surgical resection**   **3.28**\                            **0.004**   **3.89**\          **0.002**   **3.45**\           **\<0.0001**   **2.22**\           **0.042**
                                                       **(1.44--7.45)**                                 **(1.64--9.22)**               **(1.75--6.79)**                   **(1.03--4.79)**    

  **R1 vs. R0 resection**                              **2.83**\                            **0.013**                                  **3.94**\           **\<0.0001**                       
                                                       **(1.25--6.44)**                                                                **(2.15--7.24)**                                       

  **ypN+ vs. ypN0**                                    1.97\                                0.120                                      **4.71**\           **\<0.0001**   **2.70**\           **0.010**
                                                       (0.83--4.64)                                                                    **(2.35--9.43)**                   **(1.27--5.74)**    

  **ypT4 vs. ypT1 to 3**                               **4.47**\                            **0.008**                                  **19.35**\          **\<0.0001**   **4.58**\           **0.002**
                                                       **(1.48--13.46)**                                                               **(8.46--44.26)**                  **(1.72--12.19)**   

  **Harvested lymph nodes \<12**                       0.98\                                0.963                                      0.79\               0.542                              
                                                       (0.41--2.31)                                                                    (0.38--1.66)                                           

  **Poor differentiation**                             2.05\                                0.175                                      0.58\               0.164                              
                                                       (0.72--5.75)                                                                    (0.27--1.25)                                           

  **ymrTRG 4-5 vs. 1 to 3**                            1.74\                                0.204                                      **4.09**\           **\<0.0001**                       
                                                       (0.73--4.12)                                                                    **(2.08--8.02)**                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

L-TME stands for laparoscopic total mesorectal excision; APR, for abdominoperineal resection; CRM, for circumferential resection margin; T, for tumor stage; N, for node stage; HR, for hazards ratio; and CI, for confidence interval.

HR \<1 indicates an improvement in survival (positive prognostic factor); HR \>1 indicates worse survival (negative prognostic factor).

Significant *p* values are in bold characters.

^\*^After removing patients deceased during the postoperative period (*n* = 1).

Concordance between histopathologic and restaging MRI assessments {#s2_6}
-----------------------------------------------------------------

The PPVs of ymrT staging to correctly identify the ypT0 stage, ypT1/T2 stages, and ypT3/T4 stages were, respectively, 83%, 55.7%, and 68.8%. The PPVs of ymrN staging to correctly identify the ypN0 stage and ypN+ stages were, respectively, 87.7%, and 62.5%. Positive EMVI on the surgical specimens was found in 19/170 patients. The sensitivity, specificity, PPV, and NPV of ymrEMVI were, respectively, 68.4%, 78.8%, 28.8% and 95.2%. The pCR rate (ypT0N0V0) of the specimens was 39/170 patients. The sensitivity and specificity of ymrTRG 1 to 3 to identify pCR were 100% and 29%, respectively, with a false-positive rate of 70.9%. The sensitivity and specificity of ymrTRG 1 to identify pCR were 76.9% and 89.3%, respectively, with a false-positive rate of 10.7%. The PPV and NPV were 68.2% and 92.8%, respectively.

DISCUSSION {#s3}
==========

By analyzing pretreatment and restaging MRI characteristics together with the clinical and histopathological outcomes, the present results suggest that pelvimetry and restaging MRI are of interest to predict surgical difficulties and surgical outcomes (i.e., successful resection) as well as to identify pCR to NCRT, which is necessary to tailor treatment strategies in LARC patients. However, the multivariate analyses support that the main independent predictor of OS and DFS in patients with mid- and low rectal cancer is the achievement of complete mesorectal excision with clear resection margins.

The usefulness of measuring the pelvic bony dimensions by pelvimetry on MRI remains debated, although several studies have correlated certain pelvis characteristics with indicators of surgical difficulties, such as operative time and blood loss \[[@R9]--[@R11], [@R28]--[@R31]\]. In general, surgery is usually easier in females who present with a shallower and larger pelvis \[[@R11], [@R32]\]. Ferko *et al.* \[[@R29]\] found that the pelvic entrance dimension was correlated with the quality of the TME. Killeen *et al.* \[[@R10]\] reported that only pelvic outlet measurements (e.g., angles 2 and 3) were independently associated with operative time, without differences between sex, age, and CRM status. Salerno *et al.* \[[@R11], [@R30]\] demonstrated an important overlap between male and female pelvimetry, with the most significant gender-related differences at the level of the transverse mid-inlet and pelvic outlet diameter \[[@R11]\]. However, the authors concluded that CRM positivity cannot be predicted by pelvimetry in patients with rectal cancer, expect for tumor height \[[@R30]\]. More recently, Escal *et al.* \[[@R31]\] identified the mesorectal fat area and the intertuberous distance as the most predictive measurements, which were included together with the need for coloanal anastomosis and the patient BMI in a predictive score to grade the risk of surgical difficulty. The present study confirmed that male and female patients are substantially different in their pelvis anatomy and mesorectal package \[[@R11], [@R33]\] and that few transverse pelvic dimensions are indeed predictors of surgical difficulties. It is noteworthy that most of the previously published studies considered heterogeneous samples of patients with different tumor locations, treatment protocols (e.g., with or without CRT), and surgical approaches \[[@R9]--[@R11], [@R28], [@R29], [@R31], [@R34]\]. This may bias the association between the bony structures assessed by pelvimetry and the surgical outcomes if the tumor characteristics, especially in the restaging MRI, are not taken into account. To the best of our knowledge, this is the first time that pelvimetric parameters are considered together with the characteristics of the surrounding soft tissues and organs, as well as the tumor features assessed on both the pretreatment and the restaging MRIs in a homogenous sample of patients with only mid- or low rectal cancer who underwent the same therapeutic protocol including NCRT and laparoscopic total mesorectal excision. The results show that, among all considered variables, only the transverse measure of the pelvis mid-plane and the pelvis deepness are related to the risk of conversion from laparoscopy to open surgery, with a larger interischiatic spinous distance and a shallow pubic tubercle height associated with a lower risk of conversion. Similarly, a larger intertuberous distance (pelvis outlet) and a larger angle between the superior anterior pubis, the sacrovertebral angle, and the mid-S3 (angle 1) are associated with a lower risk of postoperative complications. These findings support the interest in assessing transverse measures at the level of the pelvis mid-plane and outlet to identify unfavorable anatomies, which must always be related to the tumor characteristics \[[@R9], [@R10]\]. Indeed, the difficulties in the tumor resection are potentially influenced by the delimiting bony structures, but the chance to obtain a successful resection seems to be independent of the anatomic features rather being determined by the tumor characteristics and, most importantly, by the CRM.

Other predictors of surgical difficulties were the tumor volume, the tumor height, and the ymrCRM\<2 mm, all assessed on the restaging MRI. Precisely, greater ymrTumor volumes were significantly associated with a longer operative time and higher risk of conversion, whereas a greater tumor height was associated with increased blood loss. A ymrCRM\<2 mm was a risk factor for the occurrence of postoperative complications and reduced the chance of obtaining a successful resection.

Previous studies reported an overall high accuracy of restaging MRI in excluding CRM involvement \[[@R27]\], which is known to be a significant predictor of distant and local recurrence \[[@R35], [@R36]\]. In this study, CRM assessment on the restaging MRI was the only significant predictor of achieving a successful or unsuccessful resection. Moreover, a CRM\<2 mm, assessed on both pretreatment and restaging MRI, was found to be a predictor of DFS, although it was no more significant when analyzed in the regression model. Conversely, an ymrT stage greater than T3b, an ypT4 stage and an ypN+, together with the successful resection, remained significantly associated with DFS in the multivariate analysis. For the OS, only the achievement of a successful resection was a significant predictor, with an almost four-fold increased risk of worsened survival for patients experiencing unsuccessful resection. These results confirmed the role of T and N staging as prognostic factors \[[@R37]--[@R39]\]; pathologic T4 stage and N+ stages are known to be associated with worse survival \[[@R12]\], but interestingly, an ymrT stage greater than T3b also resulted as a significant predictor of DFS in patients with LARC, supporting that advanced stage tumors and poor responders are more vulnerable to local and distance recurrence \[[@R39]--[@R41]\]. In addition, the present results stress the importance of achieving complete mesorectal excision with clear resection margins to improve patient\'s OS and DFS rates \[[@R14], [@R42]\]. Once again, it appears that surgery has a cardinal role in the management of LARC, and the oncological adequacy of the surgical resection has a drastic impact on survival independently from the T and N stages or R resection.

Restaging MRI has been proposed as a tool to identify poor responders to NCRT, optimize systemic treatment before rectal cancer resection, and estimate surgical difficulties and outcomes \[[@R27], [@R43]\]. Thus, restaging MRI may have an essential role in tailoring the therapeutic approach to the specific patient and tumor characteristics, which imply the adoption of the best surgical techniques, including laparoscopic \[[@R14], [@R17], [@R19]\], robotic \[[@R44], [@R45]\] or transanal surgery \[[@R46], [@R47]\], as well as the best adjuvant treatment, if needed. However, based on a recent meta-analysis, restaging MRI was considered not accurate enough for clinical application and highly variable depending on the different T stages \[[@R27]\]. The present study suggests that restaging MRI has a good PPV for the detection of T0 stages but the PPV drastically decreases for T stages ≥1, confirming that the accuracy of MRI for restaging LARC varies depending on the different T stages \[[@R22], [@R25], [@R27]\]. The assessment of ymrEMVI shows acceptable sensitivity and specificity, but a patient with a positive ymrEMVI has only a 28.8% chance of actually having vascular invasion. As known, the PPV is influenced by the sensitivity of the test and the prevalence of the disease in the analyzed population; in this case, only 19/170 patients (11.17%) had a positive EMVI, thus limiting the observed PPV compared to other studies in which the accuracy of ymrEMVI was higher \[[@R24], [@R48], [@R49]\]. Using ymrTRG to identify patients with a pCR would be of cardinal importance in the choice of the therapeutic approach. Bhoday *et al.* \[[@R22]\] suggested that ymrTRG 1 to 3 were the best ways of searching for patients who are suitable for deferral of surgery. In the present study, 100% sensitivity in detecting pCR was found by considering ymrTRG 1 to 3 but with a very low specificity and a high false-positive rate that limited the accuracy of restaging MRI. Indeed, to reliably and accurately identify complete responders to NCRT that may be good candidates for the "watch and wait" approach, restaging MRI should be associated with adequate sensitivity, specificity, PPV and NPV. A better balance between these parameters is found by considering only ymrTRG 1, which is associated with 76.9% of sensitivity, 89.3% of specificity, 68.2% of PPVs, and 92.8% of NPVs. In other words, an ymrTRG 1 in the restaging MRI will identify almost all patients with a pCR at the time of surgery, with a 10.7% false-positive rate. However, the threshold of the false-positive rate that can be considered acceptable in clinical practice to opt for deferral of surgery remains to be established, leaving the role of restaging MRI or other promising diagnostic tools (e.g., PET-MRI) to be further assessed in future studies.

The present study has strengths and limitations. It considered a relatively large sample of patients presenting with homogenous clinical and histopathological characteristics that were treated with the same therapeutic protocol for locally advanced mid and low rectal cancer. The available pretreatment and restaging MRIs were reevaluated by only one highly experienced radiologist using standardized measurements, which increased the reliability of the analyzed data \[[@R11], [@R21], [@R22], [@R24], [@R39]\]. However, as a retrospective multicentric study involving 4 high-volume referral hospitals, the results should be interpreted by taking into account potential selection bias and limited external validity.

In conclusion, in the management of locally advanced rectal cancer, successful surgical resection including complete mesorectal excision and clear resection margins is the main independent predictor of OS and DFS. Thus, any attempt should be made to achieve successful tumor resection. Pelvimetry and restaging MRI may be useful to predict surgical difficulties and surgical outcomes. In particular, restaging MRI can be used to identify responders to NCRT and optimize treatment by a tailored therapy, which may include different surgical strategies up to a conservative "watch and wait" approach.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The EuMaRCS is a multicenter study group involving four European referral hospitals: Henri Mondor University Hospital of Créteil, France; Doctor Peset University Hospital of Valencia, Spain; Geneva University Hospital of Geneva, Switzerland; and Vall d'Hebron University Hospital of Barcelona, Spain. All participating centers contributed to build a database of patients diagnosed with LARC who underwent MRI before and after NCRT between January 2010 and January 2016.

To be included in the study, patients should have been diagnosed with histologically proven, locally advanced (American Joint Committee on Cancer (AJCC) stages I to IIIc) \[[@R50]\] mid or low rectal cancer (up to 12 cm from the anal verge); they should have completed a long-course NCRT with a total radiation dose of 45--50.4 Gy delivered in daily fractions of 1.8--2 Gy over a 5- to 6-week period combined with 5-fluorouracil or capecitabine (Xeloda) \[[@R51]\]; they should have undergone MRI including diffusion-weighted magnetic resonance imaging (DWI) before (pretreatment MRI) and after (restaging MRI) NCRT \[[@R21]\]; and they should have been operated on by elective ''up-to-down'' laparoscopic anterior resection (LAR) with total mesorectal excision (L-TME) \[[@R5], [@R52]\] or laparoscopic abdominoperineal resection (L-APR) \[[@R53], [@R54]\]. L-APR with colostomy construction was performed for cancer infiltrating the anal sphincter not separable from the external sphincter muscles \[[@R12]\]. Conversion was defined by the need for midline laparotomy to complete the operation \[[@R55]\]. All procedures were carried out by senior colorectal surgeons experienced in minimally invasive surgery.

After the treatments, the patients were followed every 3 months for the first 2 years and every 6 months thereafter. Blood tests with biomarkers were requested at each visit; full colonoscopy was routinely performed 1--2 years after surgery and then once every 4 years. If tumor recurrence was suspected, MRI and/or PET-CT were performed to confirm the diagnosis.

The study was conducted in accordance with the ethical principles described in the Declaration of Helsinki.

Study outcomes {#s4_2}
--------------

The following patient- and tumor-related variables were collected and analyzed: demographic and clinical characteristics, MRI and NCRT data, operative and postoperative outcomes (including postoperative complications classified by Dindo-Clavien \[[@R56]\] and anastomotic leakage classified by the International Study Group of Rectal Cancer criteria \[[@R57]\]), tumor recurrence rate, overall survival (OS) and disease-free survival (DFS) rates, and pathologic assessment. The pathologic assessment (yp) included the quality of the mesorectum (i.e., complete, nearly complete, or incomplete \[[@R58]\]), the radicality of surgery (i.e., R0), and the number of harvested lymph nodes. The involvement of the circumferential resection margins (ypCRM) was defined as ≤1 mm distance between the deepest cancer invasion and the surgical resection margin \[[@R15], [@R58]\], and the involvement of the distal resection margins (ypDRMs) was defined as ≤1 mm between the closest tumor to the cut edge of the tissue \[[@R15]\]. Surgical oncologic success was defined as meeting all the following criteria: i) clear ypCRM, ii) clear ypDRM, and iii) complete mesorectal excision quality \[[@R14]--[@R16]\]. The tumor regression grade (TRG) was classified according to the 5-point scale of Mandard \[[@R59]\]. A pathologic complete response (pCR) was defined as the absence of gross and microscopic tumor cells in the specimen in accordance with the nodal status, and in the vasculature beyond the muscularis propria (ypT0N0V0) \[[@R5], [@R22], [@R24]\]. When only acellular mucinous bands were observed, the response was considered complete \[[@R60]\].

Imaging evaluation {#s4_3}
------------------

Pretreatment MRI was used for primary tumor staging; restaging MRI was performed 6 to 8 weeks after completion of NCRT and was used for tumor restaging and tumor response evaluation. All MRIs were performed according to standard protocols (2-dimensional T2-weighted fast spin-echo sequences in 3 orthogonal directions and an additional diffusion-weighted sequence in the axial plane) \[[@R21]\]. All MRI data were reanalyzed and measured by one radiologist (FP) highly experienced in MRI studies and blinded to the patients' clinical and histopathological information. The intra-examiner agreement was tested before initiating MRI re-evaluations and showed an intra-class correlation coefficient \>0.9.

Pelvimetry was realized on the pretreatment MRI according to previously published criteria providing transverse, sagittal, angles, and surface measures \[[@R10], [@R11], [@R28]--[@R31], [@R61]\]. This approach produced 26 individual pelvimetric values describing the width, depth and angles of the lesser pelvis for each patient \[[@R29]\] (Figure [2](#F2){ref-type="fig"}). The surface was calculated in cm^2^ between different reference points of the pelvis \[[@R31]\]; the rectal surface and the mesorectal surface (horizontal plane) were evaluated at the level of the junction between the high and mid-rectum and the mid- and low rectum. Surface measures were made perpendicular to the rectum axis. In addition, 4 derivate measures were taken \[[@R10], [@R11]\].

![Schematic representation of the main pelvimetric measurement on the pretreatment MRI\
(**A**) Transverse measures: 1) Interichiatic spinous distance; 2) Intertuberous distance; 3) Interacetabular distance. (**B**) Sagittal measures: 4) AB: S3 to promontory distance; BC: S3 to coccyx distance; CD: Pubic symphysis to the tip of the coccyx distance (pelvic outlet length); AE: Promontory to pubic symphysis distance (pelvic inlet length); CF: mid-inlet length (pelvic depth); 5) Promontory to coccyx distance and pubic tubercle height; 6) Length of anterior sacro-coccigeal curve. (**C**) Angles: 7) Angle 1: superior anterior pubis -- sacrovertebral angle -- mid-S3; Angle 2: sacrovertebral angle -- mid-S3 -- coccyx; Angle 3: mid-S3 -- coccyx -- inferoposterior pubis; Angle 4: coccyx -- inferoposterior pubis -- superior anterior pubis; Angle 5: inferoposterior pubis -- superior anterior pubis -- sacrovertebral angle. 8) Promontory to the top of the pubic symphysis angle; 9) Promontory to the lowest tip of the public symphysis angle. (**D**) Surface measures: 10) Surface of the sacrum-coccyx concavity; 11) Lesser pelvis surface; 12) Mesorectal surface at the level of mid-high rectum junction. MRIs were performed according to standard protocols with an external surface coil (on a 1,5T or 3T MRI system). All protocols should have at least 3DT2 weighted or 2DT2 weighted sequences in 3 planes. The axial T2-weighted sequences were angled perpendicular to the tumor axis as defined on sagittal T2-weighted images. Slice thickness for axial sequences should be ≤3 mm. A diffusion-weighted sequence including at least a *b*-value of ≥800 should be included in the restaging MRI protocol.](oncotarget-09-25315-g002){#F2}

On the pretreatment MRI, cT stage, cN stage and extramural venous invasion (EMVI) status were assessed according to previously published criteria \[[@R39], [@R62]\]. On the restaging MRI, the degree of response to the NCRT (ranging from 1 to 5) was evaluated based on the magnetic resonance tumor regression grade (mrTRG) score \[[@R63], [@R64]\], with a mrTRG of 4 or 5 identifying poor responders \[[@R22]\]. The mrEMVI was assessed as described by Chand *et al.* \[[@R24]\]. Tumor volume was assessed on both pretreatment and restaging MRI as described by Lambregts *et al.* \[[@R21]\].

Statistical analysis {#s4_4}
--------------------

To investigate eventual gender-related differences in pelvimetry measurements and surgical outcomes, males and females were compared by using chi-square test, Fisher\'s exact test, or Mann--Whitney *U* test. Differences between pretreatment and restaging MRI were assessed by using repeated measures ANOVA. Binary, multimodal, or linear regression analyses (backward models) were performed to assess predictors of surgical difficulties (i.e., estimated based on operative time, blood loss, and conversion rate) \[[@R31], [@R65], [@R66]\] and surgical success (i.e., postoperative complications and successful resection rate) \[[@R14]\] by including in the multivariate analysis all variables that reached a *p* value \< 0.2 in the univariate analysis. The OS and DFS rates at 1, 2 and 3 years were analyzed using the Kaplan--Meier method and compared between groups using the log rank (Mantel--Cox) test. Potential prognostic factors of survival were evaluated by Cox proportional hazards models. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated between the histopathological assessment and the restaging MRI parameters. Statistics were performed using SPSS (Statistical Package for Social Science, IBM SPSS Statistics, Version 23 for Macintosh; IBM Corp., Armonk, NY, USA). A *p* value \< 0.05 was considered statistically significant.
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